GlpBio产品文献引用

Nature
610.7931 (2022): 366-372

Nature
618, 1017–1023 (2023)

Cell
183.7 (2020): 1867-1883

Cell Research
31, 1291–1307 (2021)

Cell Research
33, 273–287 (2023)

Cell Research
33, 546–561 (2023)

Molecular Cancer
21.1 (2022): 1-17

Molecular Cancer
21.1 (2022): 1-18

Cancer Cell
39 (2021): 1-16

Cell Host Microbe
30.8 (2022): 1124-1138

Cell Host Microbe
31.5 (2023): 766-780

Cell Host Microbe
31.3 (2023): 418-43

Cell Metabolism
34.2 (2022): 240-255

Ann Rheum Dis
82(4): 533-545 (2023)

Cell Mol Immunol
20, 264–276 (2023)

Adv Funct Mater
33.35 (2023): 2214998

Description

ODN 1826 sodium is a specific agonist of TLR9. It is commonly used in the research of immune regulation and vaccine adjuvants, and can also be used in the study of atherosclerosis^[1][2].

ODN 1826 (1μg/mL, 24h) significantly increased the production of NO and iNOS in RAW 264.7 macrophages compared to the negative control^[3]. ODN 1826 (3μM, 48h) can increase the cell viability of RAW 264.7 cells even after γ-irradiation. Additionally, ODN 1826 (3μM, 16h) can protect mouse splenocytes from apoptosis induced by γ-irradiation^[4].

ODN 1826 (3mg/kg/d, 9 days, i.p.) significantly inhibited tumor growth (up to 40%) compared with animals treated with control ODN or saline in the pancreatic adenocarcinoma mouse model^[5]. ODN 1826 (0.05mg; days 1, 3, 5, 8, 10, and 12; i.p.) significantly delayed tumor growth, decreased tumor weight, and increased apoptosis of tumor cells in the Lewis lung cancer mouse model^[6].

References:
[1] Zhang X, Gao M, Ha T, et al. The toll-like receptor 9 agonist, CpG-oligodeoxynucleotide 1826, ameliorates cardiac dysfunction after trauma-hemorrhage. Shock. 2012;38(2):146-152.
[2] Krogmann AO, Lüsebrink E, Steinmetz M, et al. Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice. PLoS One. 2016;11(1):e0146326.
[3] Utaisincharoen P, Anuntagool N, Chaisuriya P, et al. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin Exp Immunol. 2002;128(3):467-473.
[4] Sohn WJ, Lee KW, Choi SY, et al. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death. Mol Immunol. 2006;43(8):1163-1171.
[5] Tepel J, Dagvadorj O, Kapischke M, et al. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis. 2006;21(4):365-372.
[6] Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm. 2011;26(2):203-208.

ODN 1826 sodium是一种TLR9的特异性激动剂。它通常用于免疫调节和疫苗佐剂的研究，也可用于动脉粥样硬化的研究^[1][2]。

与阴性对照相比，ODN 1826（1μg/mL，24h）显著增加了RAW 264.7巨噬细胞中一氧化氮（NO）和诱导型一氧化氮合酶（iNOS）的产生^[3]。ODN 1826（3μM，48h）即使在γ射线照射后也能增加RAW 264.7细胞的细胞活力。此外，ODN 1826（3μM，16h）可以保护小鼠脾细胞免受γ射线诱导的细胞凋亡^[4]。

在胰腺腺癌小鼠模型中，与接受对照ODN或生理盐水治疗的动物相比，ODN 1826（3mg/kg/d，9天，腹腔注射）显著抑制了肿瘤生长（高达40%）^[5]。在Lewis 肺癌小鼠模型中，ODN 1826（0.05mg，第1、3、5、8、10和12天，腹腔注射）显著延迟了肿瘤生长，降低了肿瘤重量，并增加了肿瘤细胞的凋亡^[6]。

实验参考方法

Cell experiment [1]:
Cell lines	Mouse macrophage cell line RAW 264.7
Preparation Method	RAW 264.7 macrophages (1×10⁶ cells/well) were incubated with different concentrations of ODN 1826 or ODN 1982 (negative control) for 24h. The production of NO was determined by measuring the quantity of nitrite in the supernatant from the cells cultured under different conditions by the Griess method, using a standard curve constructed with nitrite ranging from 5 to 40μM. E. coli LPS at concentration of 10ng/ml was used as a positive control. The production of iNOS (inducible NO synthase) was determined by immunoblotting. The mouse macrophages were lysed in lysis buffer containing 62.5mM Tris pH 6.8, 6M urea, 10% glycerol, 2% SDS, 0.003% bromphenol blue and 5% 2-mercaptoethanol and followed by sonication on ice for 20s. The lysates were electrophoresed on 8% polyacrylamide before transferring to polyvinylidene difluoride (PVDF) membrane. The membrane was blocked in 5% skim milk for 1h before reacting overnight with rabbit polyclonal antibody to mouse iNOS. The blots were then reacted with horseradish peroxidase-conjugated swine antirabbit IgG. Protein bands were detected by enhanced chemiluminescence.
Reaction Conditions	1μg/mL, 24h
Applications	ODN 1826 significantly increased the production of NO and iNOS in RAW 264.7 macrophages compared to the negative control.
Animal experiment [2]:
Animal models	Pancreatic adenocarcinoma mouse model
Preparation Method	For orthotopic injection, PancTuI cells were trypsinized, washed twice in PBS, resuspended in serum-free RPMI 1640 at a concentration of 10⁷ cells/ml and stored on ice. The viability of the cells was proven by a trypan blue dye exclusion test. General anaesthesia was induced using fentanyl (0.05mg/kg), midazolam (1mg) and medetomidin (0.5mg/kg). A median laparotomy was performed and the pancreas was identified. Thirty microliters of the tumour cell suspension was injected into the corpus of the pancreas. The abdominal wall was closed using Vicryl 6/0. The recovery was carefully supervised with red light rewarming and volume substitution. Seven days after tumour cell injection was performed as described above, mice were randomly assigned either to one of the different treatment groups or to the control group and received a daily intraperitoneal (i.p.) injection of ODN 1826 or ODN 1982 (control ODN) (3mg/kg in 250μL of 0.9% saline) or placebo (250μL of 0.9% saline) over 3 days. Within 21 days, this procedure was repeated three times at intervals of 3 days each (t1-3 q3t). Twenty-eight days after inoculation, animals were sacrificed by carbon dioxide intoxication and the tumour in the pancreas was removed and weighed. Length, width and height were measured and the tumour volume was calculated using the formula recommended in a meta-analysis by Tomayko and Reynolds.
Dosage form	3mg/kg/d, 9 days, i.p.
Applications	ODN 1826 significantly inhibited tumor growth (up to 40%) compared with animals treated with control ODN or saline.
References: [1] Utaisincharoen P, Anuntagool N, Chaisuriya P, et al. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin Exp Immunol. 2002;128(3):467-473. [2] Tepel J, Dagvadorj O, Kapischke M, et al. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis. 2006;21(4):365-372.

化学性质

Cas No.		SDF
别名	CpG 1826 sodium
分子式		分子量	6804
溶解度		储存条件	-20°C, sealed storage, away from moisture
General tips	请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。
Shipping Condition	评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。

溶解性数据

制备储备液
		1 mg	5 mg	10 mg
	1 mM	0.147 mL	0.7349 mL	1.4697 mL
	5 mM	0.0294 mL	0.147 mL	0.2939 mL
	10 mM	0.0147 mL	0.0735 mL	0.147 mL

摩尔浓度计算器
稀释计算器
分子量计算器

计算

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积

ul

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % saline

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系GLPBIO）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。

产品文档

Quality Control & SDS

View current batch:

Purity: >97.00%

ODN 1826 sodium

Customer Reviews

B1